SAN DIEGO — Rilzabrutinib induced “fast” and “persistent” platelet count expansion for heavily treated individuals with immune thrombocytopenia, according to results of the randomized ...

SNY's Rilzabrutinib Under Review for Immune Thrombocytopenia. Sanofi has developed rilzabrutinib for treating immune thrombocytopenia (“ITP”), another rare, complex autoimmune disorder.

Rilzabrutinib is an investigational, oral reversible Bruton tyrosine kinase inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to rilzabrutinib for the treatment ...

Rilzabrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria unresponsive to antihistamines, in a phase 2 study. News & Perspective Tools & Reference CME/CE.

Pivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for rescue response, and improved physical fatigue and quality of life measures in patients with persistent ...

Rilzabrutinib also led to significant improvements in bleeding (based on the Immune Thrombocytopenic Purpura Bleeding Score), with a mean change from baseline at week 25 of –0.04 with ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Rilzabrutinib demonstrated significant efficacy and a rapid onset of action in alleviating itch and hives in patients with moderate to severe chronic spontaneous urticaria (CSU) whose condition ...

ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP Pivotal phase 3 data show rapid and durable platelet response, reduced ...

In addition to ITP, rilzabrutinib is being studied across a variety of immune-mediated diseases. Positive results from a phase 2 study of rilzabrutinib in warm autoimmune hemolytic anemia (wAIHA) and ...